GNPX
Price
$4.12
Change
-$0.49 (-10.65%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
7.48M
Intraday BUY SELL Signals
OMER
Price
$6.27
Change
-$0.62 (-9.00%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
469.24M
110 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GNPX vs OMER

Header iconGNPX vs OMER Comparison
Open Charts GNPX vs OMERBanner chart's image
Genprex
Price$4.12
Change-$0.49 (-10.65%)
Volume$160
Capitalization7.48M
Omeros
Price$6.27
Change-$0.62 (-9.00%)
Volume$70.28K
Capitalization469.24M
GNPX vs OMER Comparison Chart in %
GNPX
Daily Signal:
Gain/Loss:
OMER
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GNPX vs. OMER commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a Hold and OMER is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (GNPX: $4.60 vs. OMER: $6.89)
Brand notoriety: GNPX and OMER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNPX: 87% vs. OMER: 27%
Market capitalization -- GNPX: $6.76M vs. OMER: $426.71M
GNPX [@Biotechnology] is valued at $6.76M. OMER’s [@Biotechnology] market capitalization is $426.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNPX’s FA Score shows that 0 FA rating(s) are green whileOMER’s FA Score has 2 green FA rating(s).

  • GNPX’s FA Score: 0 green, 5 red.
  • OMER’s FA Score: 2 green, 3 red.
According to our system of comparison, OMER is a better buy in the long-term than GNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNPX’s TA Score shows that 2 TA indicator(s) are bullish while OMER’s TA Score has 4 bullish TA indicator(s).

  • GNPX’s TA Score: 2 bullish, 8 bearish.
  • OMER’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, OMER is a better buy in the short-term than GNPX.

Price Growth

GNPX (@Biotechnology) experienced а -21.37% price change this week, while OMER (@Biotechnology) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

OMER is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OMER($469M) has a higher market cap than GNPX($7.48M). OMER YTD gains are higher at: -30.263 vs. GNPX (-89.197). GNPX has higher annual earnings (EBITDA): -17.31M vs. OMER (-125.18M). OMER has more cash in the bank: 28.7M vs. GNPX (1.6M). GNPX has less debt than OMER: GNPX (279K) vs OMER (184M). GNPX (0) and OMER (0) have equivalent revenues.
GNPXOMERGNPX / OMER
Capitalization7.48M469M2%
EBITDA-17.31M-125.18M14%
Gain YTD-89.197-30.263295%
P/E Ratio0.11N/A-
Revenue00-
Total Cash1.6M28.7M6%
Total Debt279K184M0%
FUNDAMENTALS RATINGS
GNPX vs OMER: Fundamental Ratings
GNPX
OMER
OUTLOOK RATING
1..100
8890
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10011
PRICE GROWTH RATING
1..100
9836
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OMER's Valuation (32) in the Biotechnology industry is in the same range as GNPX (37) in the Pharmaceuticals Major industry. This means that OMER’s stock grew similarly to GNPX’s over the last 12 months.

OMER's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GNPX (100) in the Pharmaceuticals Major industry. This means that OMER’s stock grew similarly to GNPX’s over the last 12 months.

OMER's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for GNPX (100) in the Pharmaceuticals Major industry. This means that OMER’s stock grew significantly faster than GNPX’s over the last 12 months.

OMER's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for GNPX (98) in the Pharmaceuticals Major industry. This means that OMER’s stock grew somewhat faster than GNPX’s over the last 12 months.

GNPX's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as OMER (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to OMER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNPXOMER
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
GNPX
Daily Signal:
Gain/Loss:
OMER
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
THC199.991.67
+0.84%
Tenet Healthcare Corp
BAER1.85-0.01
-0.54%
Bridger Aerospace Group Holdings
ATS27.14-0.33
-1.20%
ATS Corp
REPX25.92-0.44
-1.67%
Riley Exploration Permian
MITQ0.73-0.05
-6.90%
Moving iMage Technologies

GNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with NERV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
+13.58%
NERV - GNPX
64%
Loosely correlated
+0.76%
REVB - GNPX
48%
Loosely correlated
-1.77%
OMER - GNPX
45%
Loosely correlated
N/A
TOVX - GNPX
42%
Loosely correlated
+8.05%
RNXT - GNPX
31%
Poorly correlated
-6.54%
More

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with GNPX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
N/A
GNPX - OMER
45%
Loosely correlated
+13.58%
VCYT - OMER
40%
Loosely correlated
-0.84%
INM - OMER
36%
Loosely correlated
-0.57%
ZVRA - OMER
34%
Loosely correlated
-0.32%
FULC - OMER
31%
Poorly correlated
+2.58%
More